Gabrielle Agin-Liebes • UCSF Profiles

Gabrielle Agin-Liebes, PhD

Title(s)	Postdoctoral Scholar, Psychiatry
School	School of Medicine
Address
Phone	--
ORCID	gagin-liebes
vCard	Download vCard

Overview

Gabby is a clinical psychologist researcher and psychotherapist. She is currently a National Institute on Drug Abuse T32 Research Fellow in Substance Use Disorders Treatment and Services Research at UCSF. Her research explores transdiagnostic psychological mechanisms (e.g., emotion regulation, metacognition, self-transcendence) underlying the therapeutic outcomes in treatments of mood, anxiety and substance use disorders. She also conducts qualitative research on psychotherapy-related change processes. At UCSF, Gabby is conducting mechanistic research aimed at improving treatment strategies for opioid use disorder and chronic pain, with a focus on understanding approach-avoidance tendencies involved in the etiology of these co-occurring disorders. She is also exploring the use of behavioral paradigms (delay discounting), cognitive training (approach bias modification) and therapeutic interventions, including psilocybin-assisted and mindfulness-based therapies, to help prevent relapse and restore dysregulated reward systems involved in addiction.

Interests

psilocybin-assisted interventions, addiction, mindfulness-based interventions, chronic pain, opioid use disorder

ORNG Applications

Featured Publications

Websites

In The News

Faculty Mentoring

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacol Transl Sci. 2021 Apr 09; 4(2):543-552. Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Ramaekers JG, Davis AK. PMID: 33860184.

View in: PubMed Mentions:
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci. 2021 Apr 09; 4(2):553-562. Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. PMID: 33860185.

View in: PubMed Mentions:
Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol. 2020; 4(57):354-88. Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, Guss J, Bossis A, Ross S.
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020. Anderson BT, Danforth A, Daroff R, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley J, Mitchell J, Woolley J.
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Oct; 27:100538. Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. PMID: 33150319.

View in: PubMed Mentions:
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020 02; 34(2):155-166. Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S. PMID: 31916890.

View in: PubMed Mentions: 7 Fields:
Psy Psychopharmacology
Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front Pharmacol. 2018; 9:256. Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S. PMID: 29666578.

View in: PubMed Mentions:
Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol. 2017; 5(57):488-519. Swift TC*, Belser AB*, Agin-Liebes G*, Devenot N, Terrana S, Friedman HL, Guss J, Bossis AP, Ross S. [*denotes co-first authorship].
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 12; 30(12):1165-1180. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. PMID: 27909164.

View in: PubMed Mentions: 83 Fields:
Psy Psychopharmacology
Translation:Humans CTClinical Trials
The child and adolescent mental health studies program (CAMS) at New York University. Neuropsychiatrie de l'enfance et de l'adolescence. 2012; 5(60):296. Shatkin J, Agin-Liebes G. .